Abstracts tagged "Inflammation"

Abstract Number: 22 • 2012 ACR/ARHP Annual Meeting
Protective Properties of Conditioned Media From Adipose Stem Cells On Osteoarthritic Chondrocytes
Maria Isabel Guillén¹, Julia Platas¹, Vicente Mirabet², Miguel Angel Castejón³, Francisco Gomar⁴ and Maria Jose Alcaraz¹, ¹Pharmacology, University of Valencia, Burjasot, Valencia, Spain, ²Generalitat Valenciana, Valencia, Spain, ³De la Ribera University Hospital, Alzira, Spain, ⁴Surgery, University of Valencia and University Hospital, Valencia, Spain
Background/Purpose: Adipose-derived mesenchymal stem cells (ASC) exhibit a high potential for cell therapy and they might also act as a cellular source for supplying soluble…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 872 • 2012 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis
Thomas Schwartz¹, Ivar Sjaastad², Berit Flatø³, Maria Vistnes¹, Geir Christensen¹ and Helga Sanner³, ¹Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Background/Purpose : Juvenile dermatomyositis (JDM) is a vasculopathic disease affecting not only skeletal muscle and skin, but other organs as well. Previously we have shown…
Abstract Number: 1635 • 2012 ACR/ARHP Annual Meeting
Polyarthritis Caused by TIARP (TNFAIP9) Deficiency Critically Dependent On Dysregulated STAT3, NF-κB Signaling and Cell Death in Macrophage
Asuka Inoue¹, Isao Matsumoto¹, Naoto Umeda¹, Yuki Tanaka¹, Satoru Takahashi² and Takayuki Sumida¹, ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan
Background/Purpose: TNFα-induced adipose-related protein (TIARP) is a six-transmembrane protein induced by TNFα and IL-6 in adipose tissue. Recently, we found that TIARP is dominantly expressed…
Abstract Number: 832 • 2012 ACR/ARHP Annual Meeting
Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment for Rheumatoid Arthritis: A Proof-of-Concept Randomized Controlled Trial
Michelle J. Ormseth¹, Annette M. Oeser², Andrew Cunningham², Aihua Bian², Ayumi Shintani², S. Bobo Tanner³ and C. Michael Stein⁴, ¹Rheumatology, Vanderbilt Medical Center, Nashville, TN, ²Vanderbilt Medical Center, Nashville, TN, ³Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, ⁴School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disease, is associated with insulin resistance. Experimental evidence indicates that the relationship between insulin resistance and inflammation is…
Abstract Number: 1600 • 2012 ACR/ARHP Annual Meeting
Gene Targeting of an Integrin-Mediated Signaling Adaptor Molecule, Crk-Associated Substrate Lymphocyte Type Reduced the Severity of Collagen-Induced Arthritis. Its Possible Involvement in the Pathophysiology of Rheumatoid Arthritis
Satoshi Iwata, Tomoki Katayose, Yoshiko Kichikawa, Hiromi Ichihara, Hiroshi Kawasaki, Osamu Hosono, Hirotoshi Tanaka and Chikao Morimoto, Department of Rheumatology and Allergy, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Background/Purpose: It has been reported that the expression levels of β1 integrins and the ligands such as VCAM-1 are elevated in the affected joints of…
Abstract Number: 782 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis
Nigil Haroon¹, Robert D. Inman², Thomas J. Learch³, Michael H. Weisman⁴, Michael M. Ward⁵, John D. Reveille⁶ and Lianne S. Gensler⁷, ¹Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Cedars-Sinai, Los Angeles, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ⁶Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The influence of anti-TNF therapy on radiographic progression in ankylosing spondylitis (AS) is not well established. We studied this effect on radiographic progression in…
Abstract Number: 2669 • 2012 ACR/ARHP Annual Meeting
TLR7 Ligation Contributes to Monocyte Migration in Rheumatoid Arthritis
Nathan D. Chamberlain¹, Seung-jae Kim¹, Michael Volin², William Swedler³, Suncica Volkov¹ and Shiva Shahrara¹, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Department of Microbiology and Immunology, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: The aim of the study was to characterize the expression of TLR7 in rheumatoid arthritis (RA) peripheral blood (PB) cells and to examine the…
Abstract Number: 1516 • 2012 ACR/ARHP Annual Meeting
TSLP Upregulation in Human SSc Skin and Induction of Overlapping Profibrotic Genes and Intracellular Signaling with IL-13 and TGFb
Romy Christmann¹, Allison Mathes², Giuseppina Stifano², Alsya J. Affandi³, Andreea Bujor³, Cristina Padilla³ and Robert Lafyatis³, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Rheumatology, Boston University, Boston, MA
Background/Purpose: to investigate the expression of Thymic Stromal Lymphopoietin (TSLP) in diffuse cutaneous systemic sclerosis (dcSSc) patients and explore its effects in vivo and in vitro…
Abstract Number: 737 • 2012 ACR/ARHP Annual Meeting
Citrullination of ENA-78/CXCL5 Results in Conversion From a Non-Monocyte Recruiting to a Monocyte Recruiting Chemokine
Ken Yoshida¹, Olex Korchynskyi², Paul P. Tak³, Takeo Isozaki⁴, Jeffrey H. Ruth⁵, Phillip Campbell⁶, Dominique L. Baeten⁷, Danielle M. Gerlag⁷, M. Asif Amin⁸ and Alisa E. Koch⁹, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Department of Cellular Proliferation and Apoptosis, Institute of Cell Biology, Lviv, Ukraine, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Department of Medicine, University of Michigan, Ann Arbor, MI, ⁹Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification that is the conversion of arginine to citrulline in proteins mediated by peptidylarginine deiminase (PAD). Antibodies directed towards the…
Abstract Number: 1446 • 2012 ACR/ARHP Annual Meeting
The Granulocyte Signature and Organ Inflammation in TLR7 Responsive Mice Is RNA and Type 1 Interferon Dependent
Xizhang Sun¹, Alice Wiedeman², Thomas H. Teal³, Nalini Agrawal³, Jeffrey Duggan², Matt B. Buechler⁴, Jeffrey A. Ledbetter³, Denny Liggitt⁵, Jessica A. Hamerman⁶ and Keith B. Elkon⁷, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, Seattle, ⁵Comparative Medicine, University of Washington, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Rheumatology Box 356428, University of Washington, Seattle, WA
Background/Purpose: Microarray expression analysis of blood taken from patients with Systemic Lupus Erythematosus (SLE) has revealed two characteristic signatures: one that reflects exposure to type…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…
Abstract Number: 2567 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA – Associated Vasculitis
Gunnar Tomasson¹, Paul A. Monach², Kahraman Tanriverdi³, Ulrich Specks⁴, John H. Stone⁵, Linna Ding⁶, Fernando Fervenza⁴, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Carol A. Langford⁹, Deborah J. Phippard¹⁰, Philip Seo¹¹, Robert F. Spiera¹², E. William St. Clair¹³, Nadia Tchao¹⁰, Jane E. Freedman³ and Peter A. Merkel¹⁴, ¹Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland, ²Rheumatology, Boston University, Boston, MA, ³Department of Cardiology, University of Massachusetts, Wochester, MA, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA, ⁶NIAID, Bethesda, MD, ⁷Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Medicine, Duke University Medical Center, Durham, NC, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Most subjects with ANCA –associated vasculitis (AAV) respond to treatment for remission induction, but predictors for complete disease remission are lacking. We have previously…
Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe¹, Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Kathy Moser Sivils⁵, Timothy B. Niewold⁶, Gary S. Gilkeson⁷, Michael H. Weisman⁸, Mariko L. Ishimori⁸, Daniel J. Wallace⁹, David R. Karp¹⁰, John B. Harley¹¹ and Judith A. James¹², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].